Sionna Therapeutics (NASDAQ:SION – Get Free Report) released its quarterly earnings data on Thursday. The company reported ($3.38) EPS for the quarter, missing the consensus estimate of ($2.68) by ($0.70), Zacks reports.
Sionna Therapeutics Stock Performance
SION stock opened at $13.88 on Thursday. Sionna Therapeutics has a fifty-two week low of $13.20 and a fifty-two week high of $25.19.
Wall Street Analysts Forecast Growth
Several equities research analysts have recently commented on SION shares. TD Cowen started coverage on Sionna Therapeutics in a report on Tuesday, March 4th. They issued a “buy” rating for the company. Stifel Nicolaus started coverage on Sionna Therapeutics in a report on Tuesday, March 4th. They issued a “buy” rating and a $32.00 price objective for the company. Finally, Guggenheim started coverage on Sionna Therapeutics in a report on Tuesday, March 4th. They issued a “buy” rating and a $45.00 price objective for the company.
Sionna Therapeutics Company Profile
We are a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis (“CF”) patients by developing novel medicines that normalize the function of the cystic fibrosis transmembrane conductance regulator (“CFTR”) protein to deliver clinically meaningful benefit to CF patients.
Recommended Stories
- Five stocks we like better than Sionna Therapeutics
- Using the MarketBeat Stock Split Calculator
- 3 Defense Stocks Set to Benefit From Increased Military Spending
- When to Sell a Stock for Profit or Loss
- Aluminum Tariff Woes: Between 2 Stocks, 1 Shines Brighter
- What is a SEC Filing?
- Semtech Rallies on Earnings Beat—Is There More Upside?
Receive News & Ratings for Sionna Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sionna Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
